Microsoft Plans $50 Billion AI Investment to Accelerate Growth in the Global South 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
Qualcomm to Invest $150 Million in India AI Startups, Strengthening Presence in Growing Market 
Vietnam Airlines, Vietjet, and Sun PhuQuoc Airways Sign Major Boeing Aircraft Deals Amid U.S.–Vietnam Trade Talks 
YouTube Outage Disrupts Thousands Worldwide as Recommendation System Fails 
Amazon Surpasses Walmart in Annual Revenue, Signaling a New Era in Retail Competition 
Airbus Cuts Jet Production Target Amid Pratt & Whitney Engine Shortages, Q4 Profit Jumps 17% 
Nvidia Nears $30 Billion Investment in OpenAI, Replacing Previous $100 Billion AI Partnership 
Medical Groups Sue FTC Over Gender-Affirming Care Investigations Amid Trump Policy Dispute 
Boeing Secures 50 737 MAX Jet Order from Vietnam Airlines Amid Expanding Global Demand 
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
HSBC Cuts 10% of U.S. Debt Capital Markets Team Amid Ongoing Business Revamp 
Citigroup Private Bank Appoints Chad Reddy as West Market Executive in North America 
Bill Gates Pulls Out of India’s AI Impact Summit Amid Controversy and Event Mismanagement 
CAMBRIDGE, Mass., May 07, 2018 -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin® and other proprietary platforms, today announced that it will host a conference call and webcast on Monday, May 14, 2018, at 5:00 p.m. ET to report financial results for the first quarter 2018 and provide business updates.
To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 7589367. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana’s product candidate XMT-1522 is in Phase 1 clinical trials in patients with advanced tumors expressing HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC) and gastric cancer patients. The Company’s second product candidate, XMT-1536, is in Phase 1 clinical trials in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC and other cancers. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines.
Media Contact
Paul Kidwell
[email protected]
617-680-1088
Investor Contact
Stern Investor Relations, Inc.
Christina Tartaglia
[email protected]
212-362-1200
